Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes

Journal of Cell Science

Volumn 126, Issue 14, 2013, Pages 3043-3054

  Kalluru, Raja ^a   Fenaroli, Federico ^a   Westmoreland, David ^a   Ulanova, Lilia ^a   Maleki, Atoosa ^a   Roos, Norbert ^a   Madsen, Marie Paulsen ^a   Koster, Gerbrand ^a   Egge Jacobsen, Wolfgang ^a   Wilson, Steven ^a   Roberg Larsen, Hanna ^a   Khuller, Gopal K ^b   Singh, Amandeep ^b   Nyström, Bo ^a   Griffiths, Gareth ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Macrophages; Mycobacteria; Nanoparticles

Indexed keywords

COUMARIN DERIVATIVE; GREEN FLUORESCENT PROTEIN; HYDROLASE; POLYGLACTIN; RIFAMPICIN;

ANIMAL CELL; ARTICLE; BACTERIUM COLONY; BOVINE TUBERCULOSIS; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CYTOPLASM; ELECTRON MICROSCOPY; ENDOSOME; LYSOSOME; MACROPHAGE; MEMBRANE BINDING; MICROSCOPY; MOUSE; MYCOBACTERIUM BOVIS; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PH; PHAGOCYTOSIS; PHAGOLYSOSOME; PHAGOSOME; PRIORITY JOURNAL; ZETA POTENTIAL;

MACROPHAGES; MYCOBACTERIA; NANOPARTICLES;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CELL LINE; CELL MEMBRANE; COLONY COUNT, MICROBIAL; DRUG CARRIERS; FEMALE; LACTIC ACID; MACROPHAGES; MALE; MICE; MYCOBACTERIUM BOVIS; NANOPARTICLES; PHAGOSOMES; POLYGLYCOLIC ACID; RIFAMPIN;

EID: 84880665244     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.121814     Document Type: Article

References (54)

1. Anisimova, Y. V., Gelperina, S. I., Peloquin, C. A. and Heifets, L. B. (2000). Nanoparticles as Antituberculosis drugs carriers: effect on activity against mycobacterium tuberculosis in human monocyte-derived macrophages. J. Nanopart. Res. 2, 165-171.
2. Audran, R., Peter, K., Dannull, J., Men, Y., Scandella, E., Groettrup, M., Gander, B. and Corradin, G. (2003). Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 21, 1250-1255.
3. Barrow, E. L., Winchester, G. A., Staas, J. K., Quenelle, D. C. and Barrow, W. W. (1998). Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother.42, 2682-2689.
4. Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J. and Saltzman, W. M. (2009). The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30, 2790-2798.
5. Cheng, F. Y., Wang, S. P., Su, C. H., Tsai, T. L., Wu, P. C., Shieh, D. B., Chen, J. H., Hsieh, P. C. and Yeh, C. S. (2008). Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials 29, 2104-2112.
6. Couvreur, P. and Vauthier, C. (2006). Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23, 1417-1450.
7. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A. and Préat, V. (2012). PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161, 505-522.
8. Davis, M. E., Chen, Z. G. and Shin, D. M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782.
9. de Faria, T. J., Roman, M., de Souza, N. M., De Vecchi, R., de Assis, J. V., dos Santos, A. L., Bechtold, I. H., Winter, N., Soares, M. J., Silva, L. P. et al. (2012). An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages. Antimicrob. Agents Chemother. 56, 2259-2267.
10. Desjardins, M. and Griffiths, G. (2003). Phagocytosis: latex leads the way. Curr. Opin. Cell Biol. 15, 498-503.
11. Dye, C. and Williams, B. G. (2010). The population dynamics and control of tuberculosis. Science 328, 856-861.
12. Gaumet, M., Gurny, R. and Delie, F. (2007). Fluorescent biodegradable PLGA particles with narrow size distributions: preparation by means of selective centrifugation. Int. J. Pharm. 342, 222-230.
13. Gomes, A. J., Faustino, A. S., Machado, A. E., Zaniquelli, M. E., de Paula Rigoletto, T., Lunardi, C. N. and Lunardi, L. O. (2006). Characterization of PLGA microparticles as a drug carrier for 3-ethoxycarbonyl-2h-benzofuro[3,2-f]-1-benzopyran-2-one. Ultrastructural study of cellular uptake and intracellular distribution. Drug Deliv. 13, 447-454.
14. Griffiths, G., Hoflack, B., Simons, K., Mellman, I. and Kornfeld, S. (1988). The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell 52, 329-341.
15. Griffiths, G., Back, R. and Marsh, M. (1989). A quantitative analysis of the endocytic pathway in baby hamster kidney cells. J. Cell Biol. 109, 2703-2720.
16. Griffiths, G., Matteoni, R., Back, R. and Hoflack, B. (1990). Characterization of the cation-independent mannose 6-phosphate receptor-enriched prelysosomal compartment in NRK cells. J. Cell Sci. 95, 441-461.
17. Griffiths, G., Burke, B. and Lucocq, J. (1993). Fine Structure Immunocytochemistry. Berlin/New York, NY: Springer-Verlag.
18. Griffiths, G.,Nyström, B.,Sable, S.B.andKhuller, G.K.(2010).Nanobead-basedinterventionsforthetreatmentandpreventionoftuberculosis. Nat. Rev. Microbiol.8,827-834.
19. Hirota, K., Hasegawa, T., Nakajima, T., Inagawa, H., Kohchi, C., Soma, G., Makino, K. and Terada, H. (2010). Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release 142, 339-346
20. Hussain, N., Jaitley, V. and Florence, A. T. (2001). Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50, 107-142.
21. Jain, S. K., Gupta, Y., Ramalingam, L., Jain, A., Jain, A., Khare, P. and Bhargava, D. (2010). Lactose-conjugated PLGA nanoparticles for enhanced delivery of rifampicin to the lung for effective treatment of pulmonary tuberculosis. PDA J. Pharm. Sci. Technol. 64, 278-287.
22. Kjøniksen, A.L.,Joabsson, F.,Thuresson, K.andNystrom, B.(1999).Salt-inducedaggregationofpolystyrenelatexparticlesinaqueoussolutionsofahydrophobicallymodifiednonioniccellulosederivativeanditsunmodifiedanalogue. J. Phys. Chem. B103,9818-9825.
23. Jordao, L., Bleck, C. K., Mayorga, L., Griffiths, G. and Anes, E. (2008). On the killing of mycobacteria by macrophages. Cell. Microbiol. 10, 529-548.
24. Kisich, K. O., Gelperina, S., Higgins, M. P., Wilson, S., Shipulo, E., Oganesyan, E. and Heifets, L. (2007). Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int. J. Pharm. 345, 154-162.
25. Liou, W., Geuze, H. J. and Slot, J. W. (1996). Improving structural integrity of cryosections for immunogold labeling. Histochem. Cell Biol. 106, 41-58.
26. Makadia, H. K. and Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3, 1377-1397.
27. Makino, K., Nakajima, T., Shikamura, M., Ito, F., Ando, S., Kochi, C., Inagawa, H., Soma, G. and Terada, H. (2004). Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf. B Biointerfaces 36, 35-42.
28. Mathiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, M. et al. (1997). Biologically erodable microspheres as potential oral drug delivery systems. Nature 386, 410-414.
29. Muttil, P., Kaur, J., Kumar, K., Yadav, A. B., Sharma, R. and Misra, A. (2007). Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32, 140-150.
30. Nixon, D. F., Hioe, C., Chen, P. D., Bian, Z., Kuebler, P., Li, M. L., Qiu, H., Li, X. M., Singh, M., Richardson, J. et al. (1996). Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 14, 1523-1530.
31. Ohashi, K., Kabasawa, T., Ozeki, T. and Okada, H. (2009). One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 135, 19-24.
32. Onoshita, T., Shimizu, Y., Yamaya, N., Miyazaki, M., Yokoyama, M., Fujiwara, N., Nakajima, T., Makino, K., Terada, H. and Haga, M. (2010). The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf. B Biointerfaces 76, 151-157.
33. Pandey, R. and Khuller, G. K. (2004). Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J. Antimicrob. Chemother. 53, 635-640.
34. Pandey, R. and Khuller, G. K. (2006). Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian J. Exp. Biol. 44, 357-366.
35. Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G. K. and Prasad, B. (2003). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52, 981-986.
36. Panyam, J. and Labhasetwar, V. (2003a). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329-347.
37. Panyam, J. and Labhasetwar, V. (2003b). Dynamics of endocytosis and exocytosis of poly(D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 20, 212-220.
38. Panyam, J., Zhou, W. Z., Prabha, S., Sahoo, S. K. and Labhasetwar, V. (2002). Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16, 1217-1226.
39. Panyam, J., Sahoo, S. K., Prabha, S., Bargar, T. and Labhasetwar, V. (2003). Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D, L-lactide-co-glycolide) nanoparticles. Int. J. Pharm. 262, 1-11.
40. Partidos, C. D., Vohra, P., Jones, D. H., Farrar, G. and Steward, M. W. (1999). Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles. J. Control. Release 62, 325-332.
41. Quenelle, D. C., Winchester, G. A., Staas, J. K., Barrow, E. L. and Barrow, W. W. (2001). Treatment of tuberculosis using a combination of sustained-releaserifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob. Agents Chemother. 45, 1637-1644.
42. Rohde, K., Yates, R. M., Purdy, G. E. and Russell, D. G. (2007). Mycobacterium tuberculosis and the environment within the phagosome. Immunol. Rev. 219, 37-54.
43. Schliehe, C., Schliehe, C., Thiry, M., Tromsdorf, U. I., Hentschel, J., Weller, H. and Groettrup, M. (2011). Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J. Control. Release 151, 278-285.
44. Sharma, R., Saxena, D., Dwivedi, A. K. and Misra, A. (2001). Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18, 1405-1410.
45. Sharma, A., Pandey, R., Sharma, S. and Khuller, G. K. (2004a). Chemotherapeutic efficacy of poly(DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents 24, 599-604.
46. Sharma, A., Sharma, S. and Khuller, G. K. (2004b). Lectin-functionalized poly(lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54, 761-766.
47. Sharma, R., Muttil, P., Yadav, A. B., Rath, S. K., Bajpai, V. K., Mani, U. and Misra, A. (2007). Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J. Antimicrob. Chemother. 59, 499-506.
48. Shen, H., Ackerman, A. L., Cody, V., Giodini, A., Hinson, E. R., Cresswell, P., Edelson, R. L., Saltzman, W. M. and Hanlon, D. J. (2006). Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117, 78-88.
49. Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A. and Chiappetta, D. A. (2010). New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Deliv. Rev. 62, 547-559.
50. Tokuyasu, K. T. (1978). A study of positive staining of ultrathin frozen sections. J. Ultrastruct. Res. 63, 287-307.
51. Ul-Ain, Q., Sharma, S. and Khuller, G. K. (2003). Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob. Agents Chemother. 47, 3005-3007.
52. Yoshida, A., Matumoto, M., Hshizume, H., Oba, Y., Tomishige, T., Inagawa, H., Kohchi, C., Hino, M., Ito, F., Tomoda, K. et al. (2006). Selective delivery of rifampicin incorporated into poly(DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guérin. Microbes Infect. 8, 2484-2491.
53. Young, D. B., Perkins, M. D., Duncan, K. and Barry, C. E., 3rd (2008). Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest. 118, 1255-1265.
54. Zhang, Y. and Yew, W. W. (2009). Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13, 1320-1330.